Skip to Content

IRESSA 250 (Iressa 250 mg)

Generic Name: gefitinib

Pill with imprint IRESSA 250 is Brown, Round and has been identified as Iressa 250 mg. It is supplied by AstraZeneca Pharmaceuticals.

Iressa is used in the treatment of non-small cell lung cancer and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iressa 250 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for IRESSA 250

Iressa 250 mg IRESSA 250

Iressa

Generic Name
gefitinib
Imprint
IRESSA 250
Strength
250 mg
Color
Brown
Size
11.00 mm
Shape
Round
Availability
Prescription only
Drug Class
EGFR inhibitors
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
AstraZeneca Pharmaceuticals
National Drug Code (NDC)
00310-0482
Inactive Ingredients
lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate, hypromelloses, polyethylene glycol 300, titanium dioxide, ferric oxide red, ferric oxide yellow

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.